web analytics

Gynecology, Menopause and Family Planning

Tuesday, March 22, 2016

08:30-10:00 HPV: SETTING THE SCENE IN AUSTRALIA
Supported in part by Abbott
Supported in part by BD
Supported in part by Seegene
Supported in part by Seqirus
Capsule Australia is leading the world in the efforts to control cervical cancer. The most advanced vaccination program has been complemented by an imminent transition to an HPV based screening program. Reductions in high grade abnormalities have already been documented and reductions in cervical cancer are expected in the coming years.
Chairperson Suzanne Garland, Australia
F. Xavier Bosch, Spain
08:30-08:40 Introduction
10 years into HPV vaccination: The world’s perspective in cervical cancer prevention in 2016
F. Xavier Bosch, Spain
08:40-08:55 The implementation of the National HPV Vaccination program in Australia and role of the National HPV Vaccination Program Register
Julia Brotherton, Australia
08:55-09:10 Phase 4 surveillance through the National Surveillance Program: Reduction in viral circulation, and precancerous lesions
Sepehr Tabrizi, Australia
CONTROVERSIAL TOPICS IN HPV PREVENTION:
09:10-09:20 Vaccine safety and crisis management
Nigel Crawford, Australia
09:20-09:30 HPV vaccination and HPV screening in men-who-have-sex with men
Andrew Grulich, Australia
09:30-09:40 Indigenous populations: Screening participation and abnormality rates – the linkage study
John Condon, Australia
HPV self-sampling: An alternative for under-screened women
Dorota Gertig, Australia
09:40-10:00
Discussants
Discussion:
Karen Canfell, Australia
Suzanne Garland, Australia
F. Xavier Bosch, Spain
Questions to the panelists and audience:
1. Minimal surveillance protocols for developing countries
2. Herd effects VS. vaccine coverage VS. gender neutral vaccinations
3. HIV cohorts: How to prevent HPV related cancers
10:00-10:20
Coffee break
10:20-11:50 THE FUTURE OF VACCINATION AND SCREENING
10:20-10:35 The Renewal of the National Cervical Screening program and the 2017 transition to primary HPV screening
Marion Saville
10:35-10:50 The future of cervical screening in the era of HPV vaccination: Role of the Compass trial
Karen Canfell, Australia
10:50-11:05 The future of cervical cancer control: HPV vaccination and screening The HPV FASTER trials and consortium
F. Xavier Bosch, Spain
11:05-11:20 Next-generation vaccines and the Australian HPV FASTER study
Suzanne Garland, Australia
11:20-11:45
Discussants
Discussion:
Karen Canfell, Australia
Suzanne Garland, Australia
F. Xavier Bosch, Spain
Questions to the panelists and audience:
1. Prophylactic vaccines as part of the treatment for GW, RRP and CIN
2. One dose vaccination regime
3. HPV tests for screening: Clinically validated assays
11:45-11:50 Closure
Suzanne Garland,
Australia
11:50-12:10
Break
12:10-13:40
TREATMENT OF ADENOMYOSIS AND FIBROIDS
Capsule Fibroids are encountered in increasing frequency in IVF patients as the mean age of infertility patients rises. Do we have to treat them all?
Chairperson Luk Rombauts, Australia
Paula Briggs
, UK
12:10-12:40 Surgical technique for adenomyosis
Jacques Donnez, Belgium
12:40-13:10 What evidence supports that fibroids should be operated before IVF?
Zion Ben Rafael, Israel
13:10-13:40 Medical management of fibroids
Jacques Donnez, Belgium
13:40-14:30
Lunch Break
14:30-16:00 EVIDENCE-BASED BEST CLINICAL PRACTICE FOR MANAGING MENOPAUSAL SYMPTOMS
Supported in part by Fotona
Capsule There is substantial uncertainty amongst practitioners as to when and what hormonal/non-hormonal therapy to prescribe. This session will provide clinicians with an evidence-based blueprint
Chairperson Susan Davis, Australia
Sven O. Skouby, Denmark
14:30-14:50 Estrogen and progestin therapy: What to prescribe and why
Sonia Davison, Australia
14:50-15:10 Old and new options: Tibolone and TSEC
Sven O. Skouby, Denmark
15:10-15:35 Non-hormonal therapies for vasomotor symptoms: What works?
Martha Hickey, Australia
15:35-16:00 Erbium laser treatment of vaginal atrophy: Comparison with hormonal replacement therapy (HRT): 18 months follow-up
Adrian Gaspar, Argentina
16:00-16:30
Coffee break
16:30-18:00 MENOPAUSE: THE NEEDS AND THE CHALLENGES
Capsule Many studies claim that we overreacted to the WHI results. Are women suffering and why has MHT use never bounced back?
Chairpersons Susan Davis, Australia
Sonia Davison
, Australia
16:30-16:55 Menopause: How long does it last and how bad are the symptoms?
Roisin Worlsey, Australia
16:55-17:15 The WHI: Have we reached the wrong conclusions?
Robert Langer, USA
17:15-17:35 Premature Ovarian Insufficiency – meeting the treatment goals
Rodney Baber, Australia
17:35-18:00 “Doctor I can’t sleep!”
Darren Mansfield, Australia

Wednesday, March 23, 2016

08:30-09:15 ENDOMETRIOSIS
Chairpersons Jacques Donnez, Belgium
Luk Rombauts,
Australia
Debate: In Endometriosis and infertility
Immediate ART: Luk Rombauts, Australia
Immediate surgery: Kate McIlwaine, Australia
Discussion
09:15-10:00 FAMILY PLANNING
Supported by MSD
Chairpersons Jacques Donnez, France
Luk Rombauts, Australia
Conflicts in contraception
Ann Hotchin, Australia
Rochelle Hamilton, Australia
10:00-10:20
Coffee break
10:20-11:50 MENOPAUSE, BEYOND FLUSHES/FLASHES AND SWEATS
Supported in part by Fotona
Capsule The hormonal changes during menopause result in an array of health consequences, some of which will be addressed in this session
Chairpersons Robert Langer, USA
Martha Hickey, Australia
10:20-10:50 Women, Libido and Desire. An approach to rekindling desire
Cyndi Darnell, Australia
10:50-11:20 Vulvar and vaginal atrophy: Causes, presentation and treatment
Beverley Vollenhoven, Australia
11:20-11:50 Erbium Laser for Pelvic Floor Dysfunction: Australian experience
Else de Wit, Australia
11:15-12:10
Break
12:10-13:40 BREAST CANCER
Chairpersons Bruce Mann, Australia 
Roisin Worlsey,
Australia
12:10-12:40 Controversies in mammographic screening explored
Bruce Mann,
Australia
12:40-13:10 Managing menopausal symptoms after breast cancer
Martha Hickey, Australia
13:10-13:40 Genetic testing for cancer predisposition: Who should be tested and how?
Paul James, Australia
13:40-14:30
Lunch Break
14:30-16:00 FAMILY PLANNING
Capsule Thromboembolism is a threatening complication of OC’s. What is the difference between various preparations in the market?
Chairpersons Sven O. Skouby, Denmark
Kathleen McNamee, Australia
14:30-14:50 Mechanism of OC’s related thrombosis
Sven O. Skouby, Denmark
14:50-15:15 Difference in thromboembolic risk by pill type: Managing the risk
Kathleen McNamee, Australia
15:15-15:40 Recent advances in emergency contraception
Paula Briggs, UK
15:40-16:00 Use of IUS in Nulipara: Good or bad medicine
Gab Kovacs, Australia
16:00-16:30
Coffee Break
16:30-18:00 PROTECTING THE SKELETON
Capsule The prevention and treatment of osteoporosis is an important component of the care of women, but who to screen and when to intervene can be challenging.
Chairperson Sven O. Skouby, Denmark
Paula Briggs, UK
16:30-17:00 Deciding who and when to screen for osteoporosis
Susan Davis, Australia
17:00-17:30 The WHI and osteoporosis
Robert Langer, USA
17:30-18:00 Preventing bone loss and fracture: How and when to treat
Peter Ebeling, Australia